Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,275
Recruiting: 2,321
Ph III recruiting: 272
Growth YoY: +12.3%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,961)

clinicaltrialsPublishedShowing 401–450 of 636 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03678883	9-ING-41 in Patients With Advanced Cancers	active not recruiting	Phase 2	350	Actuate Therapeutics Inc.INDUSTRY	7	Apr 3, 2026	clinicaltrials
NCT05335993	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	active not recruiting	Phase 2	10	CanariaBio Inc.INDUSTRY	1	Apr 3, 2026	clinicaltrials